Take-home thoughts for R/R MM 3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice9:59 - Cost considerations for treatment options in R/R MM12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MMFacultyKathryn Maples, PharmD, BCOPClinical Pharmacy Specialist, Multiple MyelomaWinship Cancer Institute, Emory HealthcareAtlanta, GeorgiaTim Peterson, PharmD, BCOPClinical Pharmacy Specialist – Multiple MyelomaMemorial Sloan Kettering Cancer CenterNew York, New York Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.Link to full activity: https://www.proce.com/RRMM